BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steve Aselage Acquires 2,500 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Free Report) Director Steve Aselage purchased 2,500 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were purchased at an average price of $6.40 per share, for a total transaction of $16,000.00. Following the transaction, the director now owns 2,500 shares of the company’s stock, valued at approximately $16,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX traded down $0.04 during midday trading on Wednesday, hitting $6.15. The company’s stock had a trading volume of 3,061,871 shares, compared to its average volume of 3,490,228. The business’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.50. The company has a market cap of $1.27 billion, a P/E ratio of -5.75 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. The business’s quarterly revenue was up 34.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) earnings per share. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after purchasing an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares during the last quarter. Kynam Capital Management LP increased its position in shares of BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after acquiring an additional 1,927,491 shares during the last quarter. Braidwell LP increased its position in shares of BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C increased its position in shares of BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after acquiring an additional 1,964,000 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on BCRX. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.00.

Check Out Our Latest Research Report on BCRX

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.